A European phase III study of Pollinex Quattro® Birch
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Tree pollen allergy immunotherapies (Primary)
- Indications Tree pollen hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors Allergy Therapeutics
- 07 Mar 2018 According to an Allergy Therapeutics media release, data is expected in H2 2018.
- 07 Mar 2018 According to an Allergy Therapeutics media release,Status changed from planning to active, no longer recruiting.
- 18 Jul 2016 New trial record